Transthyretin cardiac amyloidosis: advances and ambiguities
Heart Failure Reviews · 29.08.2025 · 30 (6) · 1341-1352
DOI: 10.1007/s10741-025-10552-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 29.08.2025. Verfasst von Alexandrina Danilov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Prealbumin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiac amyloidosis is a fatal disorder caused by deposition of abnormally folded protein in the interstitial space. One of the proteins most associated with the disease is transthyretin (TTR), which leads to a progressive infiltrative cardiomyopathy (CM). Previously thought to be a rare disorder, there is growing recognition of it as a common cause of heart failure in the elderly and African Americans. The application of bone scintigraphy to the diagnosis of ATTR amyloidosis now allows for accurate and non-invasive diagnosis of the disease, rather than the previously necessary tissue biopsy. Targeted pharmacotherapies have been developed in the past few years that stabilize TTR, silence genes responsible for TTR production, or remove abnormal protein deposited in tissues. As of March 2025, Vutrisiran is the latest addition to the FDA-approved medications for ATTR-CM, alongside Tafamidis and Acoramidis. Several emerging therapies, including novel drugs and promising gene editing techniques are currently under investigation. As the number of available treatments continues to grow, maintaining a high index of suspicion and timely screening for the disease using laboratory tests, electrocardiography, and imaging has become increasingly important. In addition, with advancements in artificial intelligence (AI), new methods are in development to enhance screening of patients with suspected ATTR amyloidosis. These AI-driven tools could be integrated into electronic medical record systems to flag at-risk patients and allow for more rapid diagnosis. This review provides an overview of the current landscape and future directions of the diagnosis, treatment, and screening of ATTR-CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina.
- Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. yrochlani@montefiore.org.
Zitieren
APA
Danilov, A., D'Angelo, L., Marsela, E., Costabel, J. P., Jorde, U. P., & Rochlani, Y. (2025). Transthyretin cardiac amyloidosis: advances and ambiguities. Heart Failure Reviews, 30(6), 1341-1352. https://doi.org/10.1007/s10741-025-10552-9
Vancouver
Danilov A, D'Angelo L, Marsela E, Costabel JP, Jorde UP, Rochlani Y. Transthyretin cardiac amyloidosis: advances and ambiguities. Heart Failure Reviews. 2025;30(6):1341-1352. doi:10.1007/s10741-025-10552-9
BibTeX
@article{Danilov2025,
author = {Danilov, Alexandrina and D'Angelo, Lorenzo and Marsela, Enklajd and Costabel, Juan Pablo and Jorde, Ulrich P and Rochlani, Yogita},
title = {Transthyretin cardiac amyloidosis: advances and ambiguities},
journal = {Heart Failure Reviews},
year = {2025},
volume = {30},
number = {6},
pages = {1341--1352},
doi = {10.1007/s10741-025-10552-9}
}
EUVIMED